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Glutamate is the major excitatory neurotransmitter in the mammalian central nervous system
and has been associated with several cognitive functions that are known to change with age. In
rodents and humans age-related glutamate changes have been found in several brain areas. In
this cross-sectional study the presence and extent of age-associated glutamate changes in the
medial frontal cortex of healthy young adults were measured. Proton magnetic resonance
spectroscopy (1H-MRS) and brain imaging were performed at 7 T in a 2 2 2 cm3 voxel in 33
participants between 18 and 31 years old. Glutamate concentrations and grey and white matter
volume could be successfully determined at an ultra-high magnetic ﬁeld strength. Glutamate
concentrations were lower in older individuals (0.33 mM/year). This decline is in line with grey
matter thinning in the medial frontal cortex, but could not be explained by cortical thinning
alone. Therefore, the decrease in glutamate in young adulthood may be due to physiological
changes rather than anatomical changes.
& 2012 Elsevier B.V. and ECNP. All rights reserved.1. Introduction
Glutamate is the major excitatory neurotransmitter in the
mammalian central nervous system and principal neuro-
transmitter of cortical efferent systems (Fonnum, 1984).
Glutamate is involved in functions such as learning and
memory (Cotman et al., 1988), emotion and motivation
(Cobo and Mora, 1991; Mora and Cobo, 1990) and motorElsevier B.V. and ECNP. All rights
o.2012.11.003
755 0884;
recht.nl (A.-n. Marsman).behaviour (Schmidt et al., 1992). The primary location of
glutamate is in neurons and astrocytes. Only a small fraction
of the total glutamate pool is present in the extracellular
space. Glutamate is continuously released from cells and
removed from the synaptic clefts and extracellular space.
This removal is essential since exposure to high extracel-
lular glutamate concentrations can have neurotoxic effects
(Danbolt, 2001; Nedergaard et al., 2002). This neurotoxicity
has been implicated in neurodegenerative diseases like
multiple sclerosis (Westall et al., 1980), amyotrophic lateral
sclerosis (Pioro et al., 1999), Alzheimer’s dementia
(Antuono et al., 2001), Parkinson’s disease (Greenamyre,
1993) and schizophrenia (Olney and Farber, 1995). Recently,reserved.
Figure 1 Voxel placement. The voxel (2 2 2 cm3) was
placed in the medial frontal cortex in front of the genu of
the corpus callosum.
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glutamate concentrations in the frontal brain region in
schizophrenia (Marsman et al., in press), suggesting that
too low levels of intra or extracellular glutamate may also
be associated with neuropsychiatric diseases. Studying
glutamate levels in normal maturation may contribute to
elucidating the role of glutamate in cognitive decline in
health and in neurological and neuropsychiatric disorders.
Studies in rodents as well as in humans have shown that
age-related glutamate decreases occur in several brain
areas, including motor areas, sensory areas and the hippo-
campus (Banay-Schwartz et al., 1989; Kaiser et al., 2005;
Raininko and Mattsson, 2010). Using these methods, in the
rodent frontal cortex decreases in glutamate with age as
well as neuronal loss have been found (Fornieles et al.,
1986; Mufson and Stein, 1980; Segovia et al., 2001). Since
glutamate is present in most cortical neurons, the observed
decreases in glutamate may be associated with the age-
dependent neuronal pruning (Segovia et al., 2001). In
humans, the frontal cortex shows thinning with increasing
age, which could be due to shrinkage of neurons as well as
neuronal loss (Anderton, 2002; Brans et al., 2010), and
might possibly be correlated with decreases in glutamate
concentrations. Structural brain changes in the frontal
cortex in young adulthood (Hedman et al., 2012) suggest
that there are physiological changes going on during young
adulthood. However, at this point in time the physiology
underlying these structural brain changes is not well
understood.
In this study we measured glutamate concentrations in the
medial frontal brain region of healthy, young adult subjects,
using high-ﬁeld magnetic resonance spectroscopy. Proton
magnetic resonance spectroscopy (1H-MRS) can be used to
non-invasively measure metabolite concentrations in vivo.
Until now, studies investigating glutamate during aging using
1H-MRS were conducted at ﬁeld strengths of 4 T or lower.
Previous studies showed a decrease of glutamate with age in
the mesial motor cortex between 26 and 54 years (Kaiser
et al., 2005) and dorsolateral prefrontal cortex between 19
and 31 years (Grachev et al., 2001; Grachev and Apkarian,
2001), a trend of an age-related glutamate decline in frontal
white matter between 21 and 71 years (Chang et al., 2009),
and age-related increase of glutamate in the orbitofrontal
cortex between 19 and 52 years (Grachev and Apkarian,
2000). Since measurement of glutamate with 1H-MRS is
challenging at lower ﬁeld strengths, due to its spectral
overlap with glutamine, a magnetic ﬁeld strength of 7 T
was used in this study to accurately determine glutamate
concentrations in the human brain. In addition, we measured
N-acetyl aspartate (NAA), a marker of neuronal integrity,
creatine, a marker of energy metabolism, and choline, a
marker of membrane turnover (Maudsley et al., 2009). Also,
most of the previous studies compared a younger age group
with an older age group, thereby not investigating the
alterations occurring within each age group. We measured
glutamate, NAA, creatine and choline, and the fractions of
grey and white matter in the medial frontal cortex, which is
an area that decreases in volume in young adulthood (Brans
et al., 2010), and has been reported to be decreased in
schizophrenia (Hulshoff Pol et al., 2001). With this study, we
investigate the relation between glutamate levels in the
frontal cortex and age within a group of young adults.2. Method
2.1. Subjects
37 Healthy subjects (19 men and 18 women) participated in this
study, after giving written informed consent as approved by the
Medical Ethics Committee of the University Medical Center Utrecht,
The Netherlands. Participants were between 18.3 and 31.5 years
old (mean7SD=24.873.4 years). Participants had no major psy-
chiatric or neurological history and no history of drug or alcohol
abuse, as tested with the Mini International Neuropsychiatric
Interview Plus (MINI-Plus) (Van Vliet et al., 2000). Participants
had no ﬁrst-degree relatives with psychiatric or neurological
disorders. Four volunteers were excluded from the study due to
poor quality of MR spectra or the T1-weighted image. Hence, the
results of this study are based on 33 subjects.
2.2. MRS acquisition
1H-MRS experiments were performed on a 7 T whole body MR
scanner (Philips, Cleveland, USA) with a birdcage transmit
head coil (Nova Medical, Inc., Burlington, MA, USA) in combination
with a 16-channel receive coil (Nova Medical, Inc., Burlington,
MA, USA). First, a T1-weighted MP-RAGE sequence (450 slices,
slice thickness=0.8 mm, TR=7 ms, TE=3 ms, ﬂip angle=81,
FOV=250 200 180 mm3, 312 312 acquisition matrix, SENSE
factor 2.7, scan duration=408 s) was obtained for anatomical
reference and grey and white matter tissue classiﬁcation.
After obtaining the anatomical image, MR spectra were acquired
of the medial frontal brain region (Figure 1). For this, a stimulated
echo acquisition mode (STEAM) sequence (TR=2000 ms, TE=7 ms,
TM=11 ms, single voxel, voxel size=2 2 2 cm3, B1=20 mT) was
used, placing the voxel of interest in the medial frontal cortex, in
front of the genu of the corpus callosum. Water suppression was
applied (SWAMP (De Graaf and Nicolay, 1998)) for obtaining the MR
spectrum with glutamate, NAA, creatine and choline (acquisition
time=260 s). An MR spectrum without water suppression was
obtained for quantiﬁcation (carrier frequency was set to the
chemical shift of H2O, acquisition time=10 s). Second order B0
shimming was based on the FASTERMAP algorithm (Gruetter, 1993;
Gruetter and Boesch, 1992). After selecting the volume of interest,
local B1 ﬁeld was calibrated (Versluis et al., 2010). Besides
glutamate, we also quantiﬁed NAA, creatine and choline.
A. Marsman et al.14862.3. Spectral ﬁtting and quantiﬁcation
Spectral ﬁtting was performed using the Accurate Quantitation of
Short Echo time domain Signals (AQSES) algorithm, implemented in
the Simulation Package based on In vitro Databases (SPID) (Poullet
et al., 2007).
Metabolite levels were estimated using the water signal as an
internal reference. The concentration of each metabolite was
calculated as follows:
met½  ¼
signalmet
signalwater
n volGMn waterGM½ ð Þþ volWMn waterWM½ ð Þþ volCSFn waterpure
  
volGMþvolWM
 !
ð1Þ
where [met] is the metabolite concentration, signalmet the area
under the curve of the metabolite spectrum and signalwater the area
under the curve of the water spectrum; volGM, volWM and volCSF
are respectively the grey matter fraction, white matter fraction
and cerebrospinal ﬂuid (CSF) fraction in the voxel; and [waterGM],
[waterWM] and [waterpure] are respectively the water concentration
in grey matter, white matter and CSF. The segmentation of the
anatomical image in grey matter, white matter and CSF fractions
was done using the software package SPM8 (http://www.ﬁl.ion.ucl.
ac.uk/spm/software/spm8). After alignment of the 1H-MRS voxel
with the anatomical scan, the grey matter, white matter and CSF
fractions in the 1H-MRS voxel was determined.2.4. Statistical analysis
For regression analyses, the general linear model (GLM) was applied
using the statistical environment R (R Development Core Team,
2006), with metabolite concentration as the dependent variable
and age, gender and grey matter fraction as independent variables.
Grey matter fraction was calculated as follows:
GMfraction¼ volGM
volGMþvolWM ð2Þ
where GMfraction is the proportion of grey matter to total brain
tissue in the 1H-MRS voxel, GM is the proportion of grey matter in
the 1H-MRS voxel, and WM is the proportion of white matter in the
1H-MRS voxel.Figure 2 A typical spectrum, as measured in this study using the
stimulated echo acquisition mode (STEAM) at a magnetic ﬁeld
strength of 7 T in a 2 2 2 cm3 voxel placed in the medial
frontal cortex (Cr=creatine, PCr=phosphocreatine, Cho=choline,
Gln=glutamine, Glu=glutamate, NAA=N-acetyl aspartate).3. Results
The glutamate resonance at 2.3 ppm was well resolved and
could be obtained with a high signal to noise ratio and good
spectral resolution as revealed by visual inspection of the
spectrum (Figure 2). The glutamate concentration in the
medial frontal cortex changed signiﬁcantly with age
(b=0.33, t=2.5, df=30, p=0.02; mean7SD=6.172.7)
(Figure 3). No signiﬁcant effects of grey matter fraction
(b=2.74, t=1.2, p=0.23) and gender (b=0.42, t=0.5,
p=0.65) were found.
NAA did not show any signiﬁcant age-related changes
(b=0.1, t=1.3, p=0.22; mean7SD=6.271.7) (Figure 4).
NAA did not have a signiﬁcant association with the grey
matter fraction in the voxel (b=2.14, t=1.4, p=0.16).
Creatine concentrations changed signiﬁcantly with age
(b=0.22, t=3.3, p=0.002; mean7SD=6.071.4) (Figure 5).
Creatine did not have signiﬁcant associations with the grey
matter fraction in the voxel (b=2.05, t=1.8, p=0.08) and
gender (b=0.68, t=1.5, p=0.15).
Choline concentrations show an age-related decrease,
however, this is not signiﬁcant (b=0.28, t=1.9, p=0.06;
mean7SD=1.570.4) (Figure 6). Choline did not have sig-
niﬁcant associations with the grey matter fraction in the
voxel (b=0.44, t=2.4, p=0.86) and gender (b=0.80, t=0.8,
p=0.44).4. Discussion
The main ﬁnding of this study is a decrease in glutamate
concentration with age in a relatively small age range from
18 to 31 years in medial frontal cortex of the human brain.
Concentrations of NAA, a marker of neuronal integrity, did
not show any signiﬁcant changes in this age range, which
indicates that there are no alterations in brain tissue orFigure 3 Linear regression analysis of age on glutamate
concentrations in the medial frontal cortex (b=0.33,
t=2.5, p=0.02).
Figure 4 Linear regression analysis of age on NAA concentrations
in the medial frontal region (b=0.07, t=1.1, p=0.28).
Figure 5 Linear regression analysis of age on creatine con-
centrations in the medial frontal region (b=0.22, t=3.3,
p=0.002).
Figure 6 Linear regression analysis of age on choline concen-
trations in the medial frontal region (b=0.28, t=1.9,
p=0.06).
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individuals. This ﬁnding is further strengthened by the fact
that grey matter volume did not reveal a signiﬁcant
inﬂuence on the age-related decline in glutamate in the
medial frontal cortex.
In healthy aging, the 1H-MRS proﬁle of the human brain
shows region-speciﬁc alterations, the largest alterations
occurring in (pre)frontal brain regions and in particular in
glutamate and GABA concentrations (Grachev et al., 2001).
Indeed, our ﬁndings corroborate that glutamate concentra-
tions decrease with age in the human frontal cortex, alreadyat a young adult age. In a meta-analysis of longitudinal MRI-
studies of whole brain volume change in healthy individuals it
was shown that there is a period of stable brain volume
between 18 and 35 years of age (Hedman et al., 2012), which
supports the suggestion that the glutamate decline observed
in this period has a physiological background and is not
primarily a reﬂection of changes in brain volume. The
alterations in glutamate concentration in the medial pre-
frontal cortex may precede changes in cortical volume or
may reﬂect the consequence of cortical changes that occur
during adolescence. During the transition from adolescence
to adulthood synaptic density decreases and (mainly) gluta-
matergic synapses are eliminated, reﬂecting synaptic pruning
(Bourgeois and Rakic, 1993; Craik and Bialystok, 2006; Sawa,
2009). Interestingly, both glutamate levels (Bustillo et al.,
2011; Cotman et al., 1988; Segovia et al., 2001) and
efﬁciency of structural and functional brain networks (Gong
et al., 2009; Lo et al., 2011; van den Heuvel et al., 2009;
Wen et al., 2011) are associated with cognitive functioning.
Thus, possibly the glutamate decline in young adulthood may
reﬂect brain maturation.
The glutamate signal that is detected in the human brain
by 1H-MRS does not distinguish between glutamate used in
metabolic pathways and glutamate used for neurotransmis-
sion. Since the majority of glutamate is present in the
metabolic pool (Fonnum, 1993), the decreases in glutamate
are possibly due to changes in metabolic activity (Segovia
et al., 2001; Zahr et al., 2008). This may reﬂect a decreased
neuronal integrity since glutamate is primarily located in
neurons. However, we did not ﬁnd any signiﬁcant age-
related decline in the concentrations of NAA, which implies
that it is unlikely that the decrease with age in glutamate
concentration in the prefrontal cortex in these young adult
humans represents changes in neuronal integrity. Indeed, it
is more likely that the age-related decline in glutamate
concentrations at this age point to changes in glutamatergic
A. Marsman et al.1488neurotransmission and neuronal metabolism. Changes in
the regulation of glutaminase, the enzyme that converts
glutamine into glutamate, are present in the aging
brain (Wallace and Dawson, 1992, 1993), which could
lead to a reduction of the glutamine–glutamate cycle ﬂux
(Boumezbeur et al., 2009). A decrease with age in the
density of the NMDA-type of glutamate receptor has also
been found (Petersen and Cotman, 1989), possibly result-
ing in reduced uptake capacity (Segovia et al., 2001). The
age-related decline in glutamate could in turn result in
reduced glutamate-receptor activation, in particular of
the NMDA-type, which may lead to cognitive deﬁcits
(Krystal et al., 1994; Olney et al., 1999). However, since
there are no signs of cognitive alterations in young
adulthood, and yet there are signs of synaptic pruning,
the decrease in glutamate might alternatively suggest a
higher efﬁciency of glutamate signalling in this period.
The latter may possibly be a result of maturation of
neural systems (Stoneham et al., 2010). In fact, the age-
related decreases that were found for concentrations of
creatine, a marker of energy metabolism, and choline, a
marker of membrane turnover, support this notion.
The development of the glutamatergic neurotransmitter
system during healthy maturation may also provide insight in
pathologies underlying neurodegenerative diseases, like schi-
zophrenia. Glutamate concentrations decrease progressively
with age in patients with schizophrenia as compared with
healthy individuals (Marsman et al., in press). Since the
results of this study show that glutamate concentrations in
healthy individuals are declining with age as well, this
implicates that glutamate levels in patients with schizophre-
nia decline at an even faster rate.
There are some points that have to be taken into
consideration when interpreting its ﬁndings. The 1H-MRS
technique that was used in this study, STEAM, has the
advantage of combining a short TE with a long TR, thereby
reducing quantiﬁcation errors due to T1 and T2 relaxations,
which are possibly age-dependent (Kreis et al., 2005;
Raininko and Mattsson, 2010). However, STEAM suffers
from signal to noise ratio (SNR) loss and only half of the
available signal can be obtained, therefore, the applica-
tion of newly developed 1H-MRS sequences for 7 T might
result in a better SNR and therefore more sensitive
measures in the future (Boer et al., 2011). Also, the use
of water as an internal reference to calculate metabolite
concentrations might induce quantiﬁcation errors, since
a possible decrease of water concentrations with age is
not considered (Chang et al., 1996; Kaiser et al., 2005).
However, between 20 and 70 years of age, water con-
centrations in the medial frontal lobe do not show any
signiﬁcant changes (Brooks et al., 2001). In this study,
only a small age range was investigated. It would be
interesting to examine glutamate levels at older ages as
well, thus acquiring a complete proﬁle of glutamate
changes throughout adult life, which could help elucidate
the physiology behind several neural processes that show
age-related alterations.
In conclusion, this study shows a decline in glutamate
concentrations in the medial frontal cortex in healthy young
adulthood and no alterations in markers of neuronal integ-
rity, suggesting there are physiological changes occurring in
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